Chargement en cours...
Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
Sorafenib, an oral multi-tyrosine kinase inhibitor, has been the first-line therapy for the treatment of patients with advanced HCC, providing a survival benefit of only three months in approximately 30% of patients. Cancer stem cells (CSCs) are a rare tumour subpopulation with self-renewal and diff...
Enregistré dans:
| Publié dans: | Curr Oncol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8293268/ https://ncbi.nlm.nih.gov/pubmed/34208001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28030200 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|